{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:00:35Z","timestamp":1777878035272,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["NASN School Nurse"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>The human papillomavirus (HPV) is the most common sexually transmitted infection in the United States despite most cases being preventable by vaccination. HPV vaccine efficacy varies in relationship to when the vaccine is administered, with greater efficacy obtained if administered prior to sexual debut. Historically, this vaccine was created to protect women from cervical cancer. As scientific knowledge of HPV-related cancers has advanced, it has become evident that HPV vaccination is a priority for both genders. HPV is known to contribute to male cancers of the mouth, throat, anus, and penis, as well as causing genital warts. This article aims to explain the benefits of HPV immunization for the gender the farthest from meeting vaccination goals, boys, and young men. This article expounds on the school nurses\u2019 role in promoting vaccination to prevent HPV infection and the sequela of related cancers.<\/jats:p>","DOI":"10.1177\/1942602x221151134","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T01:20:34Z","timestamp":1674523234000},"page":"114-120","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer Prevention Begins in Middle School: The Personal Advantages of HPV Immunization in Males"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1496-8787","authenticated-orcid":false,"given":"Jenny","family":"Gordon","sequence":"first","affiliation":[{"name":"Family Nurse Practitioner, PhD Student, Thelen Family Medicine, Fayetteville, TN"},{"name":"University of Tennessee Southern Campus Clinic, Pulaski, TN"},{"name":"University of Alabama Huntsville Joint PhD Program with the University of Alabama, Huntsville, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Bail","sequence":"additional","affiliation":[{"name":"Assistant Professor of Nursing, University of Alabama in Huntsville College of Nursing, Huntsville, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"Alemany L. Saunier M. Alvarado-Cabrero I. Quiros B. Salmeron J. Shin H. R. Pirog E. C. Guimera N. Hernandez-Suarez G. Felix A. Clavero O. Lloveras B. Kasamatsu E. Goodman M. T. Hernandez B. Y. Laco J. Tinoco L. Geraets D. T. Lynch C. F. . . . HPV VVAP Study Group. (2015). Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. International Journal of Cancer 136(1) 98-107. https:\/\/doi.org\/10.1002\/ijc.28963","DOI":"10.1002\/ijc.28963"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Anic G. M. Giuliano A. R. (2011). Genital HPV infection and related lesions in men. Preventive Medicine 53(Suppl. 1) S36-S41. https:\/\/doi.org\/10.1016\/j.ypmed.2011.08.002","DOI":"10.1016\/j.ypmed.2011.08.002"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Athanasiou A. Bowden S. Paraskevaidi M. Fotopoulou C. Martin-Hirsch P. Paraskevaidis E. Kyrgiou M. (2020). HPV vaccination and cancer prevention. Best Practice & Research Clinical Obstetrics & Gynaecology 65 109-124. https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.02.009","DOI":"10.1016\/j.bpobgyn.2020.02.009"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Calo W. A. Lennon R. P. Ruffin Iv M. T. Keller C. Spanos K. D\u2019Souza G. Kraschnewski J. L. (2022). Support for HPV vaccine school-entry requirements in the United States: The role of exemption policies. Vaccine 40(51) 7426-7432. https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.019","DOI":"10.1016\/j.vaccine.2022.08.019"},{"key":"e_1_3_3_6_1","unstructured":"Centers for Disease Control and Prevention. (2022). Cancers associated with human papillomavirus United States\u20142015\u20132019 (USCS Data Brief no. 32). Centers for Disease Control and Prevention U.S. Department of Health and Human Services. https:\/\/www.cdc.gov\/cancer\/hpv\/statistics\/cases.htm"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Chaturvedi A. K. Graubard B. I. Broutian T. Pickard R. K. L. Tong Z. Y. Xiao W. Kahle L. Gillison M. L. (2018). Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. Journal of Clinical Oncology 36(3) 262-267. https:\/\/doi.org\/10.1200\/JCO.2017.75.0141","DOI":"10.1200\/JCO.2017.75.0141"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Chesson H. W. Dunne E. F. Hariri S. Markowitz L. E. (2014). The estimated lifetime probability of acquiring human papillomavirus in the United States. Sexually Transmitted Diseases 41(11) 660-664. https:\/\/doi.org\/10.1097\/OLQ.0000000000000193","DOI":"10.1097\/OLQ.0000000000000193"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"da Costa Nunes J. F. Pires S. Chade D. C. (2020). Human papillomavirus vaccination and prevention of intraepithelial neoplasia and penile cancer: Review article. Current Opinion in Urology 30(2) 208-212. https:\/\/doi.org\/10.1097\/MOU.0000000000000730","DOI":"10.1097\/MOU.0000000000000730"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"da Rocha W. M. da Silva K. C. Cavalcanti S. M. B. (2019). The role of oncogenic DNA viruses in penile cancer development. Critical Reviews in Oncogenesis 24(4) 385-402. https:\/\/doi.org\/10.1615\/CritRevOncog.2020032961","DOI":"10.1615\/CritRevOncog.2020032961"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"de Martel C. Georges D. Bray F. Ferlay J. Clifford G. M. (2020). Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. The Lancet Global Health 8(2) e180-e190. https:\/\/doi.org\/10.1016\/s2214-109x(19)30488-7","DOI":"10.1016\/S2214-109X(19)30488-7"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Deshmukh A. A. Suk R. Shiels M. S. Sonawane K. Nyitray A. G. Liu Y. Gaisa M. M. Palefsky J. M. Sigel K. (2020). Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States 2001-2015. Journal of the National Cancer Institute 112(8) 829-838. https:\/\/doi.org\/10.1093\/jnci\/djz219","DOI":"10.1093\/jnci\/djz219"},{"key":"e_1_3_3_13_1","unstructured":"Food and Drug Administration. (2018). Prescribing information [package insert]. Gardasil 9 (human papillomavirus 9-valent vaccine recombinant). U.S. Department of Health and Human Services Food and Drug Administration. https:\/\/www.fda.gov\/media\/90064\/download"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Gerend M. A. Murdock C. Grove K. (2020). An intervention for increasing HPV vaccination on a university campus. Vaccine 38(4) 725-729. https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.028","DOI":"10.1016\/j.vaccine.2019.11.028"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Giuliano A. R. Palefsky J. M. Goldstone S. Moreira E. D.Jr. Penny M. E. Aranda C. Vardas E. Moi H. Jessen H. Hillman R. Chang Y. H. Ferris D. Rouleau D. Bryan J. Marshall J. B. Vuocolo S. Barr E. Radley D. Haupt R. M. Guris D. (2011). Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. New England Journal of Medicine 364(5) 401-411. https:\/\/doi.org\/10.1056\/NEJMoa0909537","DOI":"10.1056\/NEJMoa0909537"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Goldstone S. E. Giuliano A. R. Palefsky J. M. Lazcano-Ponce E. Penny M. E. Cabello R. E. Moreira E. D. Baraldi E. Jessen H. Ferenczy A. Kurman R. Ronnett B. M. Stoler M. H. Bautista O. Das R. Group T. Luxembourg A. Zhou H. J. Saah A. (2022). Efficacy immunogenicity and safety of a quadrivalent HPV vaccine in men: Results of an open-label long-term extension of a randomised placebo-controlled phase 3 trial. The Lancet Infectious Diseases 22(3) 413-425. https:\/\/doi.org\/10.1016\/s1473-3099(21)00327-3","DOI":"10.1016\/S1473-3099(21)00327-3"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Herrero R. Quint W. Hildesheim A. Gonzalez P. Struijk L. Katki H. A. Porras C. Schiffman M. Rodriguez A. C. Solomon D. Jimenez S. Schiller J. T. Lowy D. R. van Doorn L.-J. Wacholder S. Kreimer A. R. (2013). Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLOS ONE 8 Article e68329. https:\/\/doi.org\/10.1371\/journal.pone.0068329","DOI":"10.1371\/journal.pone.0068329"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Joura E. A. Pils S. (2016). Vaccines against human papillomavirus infections: Protection against cancer genital warts or both? Clinical Microbiology and Infection 22(Suppl. 5) S125-S127. https:\/\/doi.org\/10.1016\/j.cmi.2016.12.017","DOI":"10.1016\/j.cmi.2016.12.017"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Kaul S. Do T. Q. N. Hsu E. Schmeler K. M. Montealegre J. R. Rodriguez A. M. (2019). School-based human papillomavirus vaccination program for increasing vaccine uptake in an underserved area in Texas. Papillomavirus Research 8 Article 100189. https:\/\/doi.org\/10.1016\/j.pvr.2019.100189","DOI":"10.1016\/j.pvr.2019.100189"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Kreimer A. R. Shiels M. S. Fakhry C. Johansson M. Pawlita M. Brennan P. Hildesheim A. Waterboer T. (2018). Screening for human papillomavirus-driven oropharyngeal cancer: Considerations for feasibility and strategies for research. Cancer 124(9) 1859-1866. https:\/\/doi.org\/10.1002\/cncr.31256","DOI":"10.1002\/cncr.31256"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Laprise C. Madathil S. A. Schlecht N. F. Castonguay G. Soulieres D. Nguyen-Tan P. F. Allison P. Coutlee F. Hier M. Rousseau M. C. Franco E. L. Nicolau B. (2017). Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study. Oral Oncology 69 56-61. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.03.013","DOI":"10.1016\/j.oraloncology.2017.03.013"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Liao C. I. Francoeur A. A. Kapp D. S. Caesar M. A. P. Huh W. K. Chan J. K. (2022). Trends in human papillomavirus-associated cancers demographic characteristics and vaccinations in the US 2001-2017. JAMA Network Open 5(3) Article e222530. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.2530","DOI":"10.1001\/jamanetworkopen.2022.2530"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"McGovern J. Fuller C. Burris K. (2021). Anal cancer screening and prevention: A review for dermatologists. Journal of the European Academy of Dermatology and Venereology 35(8) 1622-1627. https:\/\/doi.org\/10.1111\/jdv.17263","DOI":"10.1111\/jdv.17263"},{"key":"e_1_3_3_24_1","unstructured":"Meeting of the Global Advisory Committee on Vaccine Safety. (2017 July 14). Geneva Switzerland."},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Meites E. Szilagyi P. G. Chesson H. W. Unger E. R. Romero J. R. Markowitz L. E. (2019). Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 68(32) 698-702. https:\/\/doi.org\/10.15585\/mmwr.mm6832a3","DOI":"10.15585\/mmwr.mm6832a3"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Miller K. Dilley S. E. Huh W. K. (2018). Lessons learned from domestic and international human papillomavirus vaccination programs: A review. American Journal of Obstetrics and Gynecology 218(5) 467-473. https:\/\/doi.org\/10.1016\/j.ajog.2017.08.109","DOI":"10.1016\/j.ajog.2017.08.109"},{"key":"e_1_3_3_27_1","unstructured":"Mission: HPV Cancer Free. (2022). The American Cancer Society. https:\/\/www.cancer.org\/healthy\/hpv-vaccine.html"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"National Association of School Nurses. (2016). Framework for 21st century school nursing practice: National Association of School Nurses. NASN School Nurse 31(1) 45-53. https:\/\/doi.org\/10.1177\/1942602X15618644","DOI":"10.1177\/1942602X15618644"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Ndiaye C. Mena M. Alemany L. Arbyn M. Castellsagu\u00e9 X. Laporte L. Bosch F. X. de Sanjos\u00e9 S. Trottier H. (2014). HPV DNA E6\/E7 mRNA and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. The Lancet Oncology 15(12) 1319-1331. https:\/\/doi.org\/10.1016\/s1470-2045(14)70471-1","DOI":"10.1016\/S1470-2045(14)70471-1"},{"key":"e_1_3_3_30_1","doi-asserted-by":"crossref","unstructured":"Olesen T. B. Sand F. L. Rasmussen C. L. Albieri V. Toft B. G. Norrild B. Munk C. Kj\u00e6r S. K. (2019). Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: A systematic review and meta-analysis. The Lancet Oncology 20(1) 145-158. https:\/\/doi.org\/10.1016\/s1470-2045(18)30682-x","DOI":"10.1016\/S1470-2045(18)30682-X"},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Osazuwa-Peters N. Adjei Boakye E. Mohammed K. A. Tobo B. B. Geneus C. J. Schootman M. (2017). Not just a woman\u2019s business! Understanding men and women\u2019s knowledge of HPV the HPV vaccine and HPV-associated cancers. Preventive Medicine 99 299-304. https:\/\/doi.org\/10.1016\/j.ypmed.2017.03.014","DOI":"10.1016\/j.ypmed.2017.03.014"},{"key":"e_1_3_3_32_1","doi-asserted-by":"crossref","unstructured":"Palefsky J. M. Giuliano A. R. Goldstone S. Moreira E. D.Jr. Aranda C. Jessen H. Hillman R. Ferris D. Coutlee F. Stoler M. H. Marshall J. B. Radley D. Vuocolo S. Haupt R. M. Guris D. Garner E. I. (2011). HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New England Journal of Medicine 365 1576-1585. https:\/\/doi.org\/10.1056\/NEJMoa1010971","DOI":"10.1056\/NEJMoa1010971"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"Petaja T. Keranen H. Karppa T. Kawa A. Lantela S. Siitari-Mattila M. Levanen H. Tocklin T. Godeaux O. Lehtinen M. Dubin G. (2009). Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. Journal of Adolescent Health 44(1) 33-40. https:\/\/doi.org\/10.1016\/j.jadohealth.2008.10.002","DOI":"10.1016\/j.jadohealth.2008.10.002"},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Phillips A. Patel C. Pillsbury A. Brotherton J. Macartney K. (2018). Safety of human papillomavirus vaccines: An updated review. Drug Safety 41(4) 329-346. https:\/\/doi.org\/10.1007\/s40264-017-0625-z","DOI":"10.1007\/s40264-017-0625-z"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Pierce Campbell C. M. Kreimer A. R. Lin H.-Y. Fulp W. O\u2019Keefe M. T. Ingles D. J. Abrahamsen M. Villa L. L. Lazcano-Ponce E. Giuliano A. R. (2015). Long-term persistence of oral human papillomavirus type 16: The HPV infection in men (HIM) study. Cancer Prevention Research 8(3) 190-196. https:\/\/doi.org\/10.1158\/1940-6207.Capr-14-0296","DOI":"10.1158\/1940-6207.CAPR-14-0296"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","unstructured":"Pingali C. Yankey D. Elam-Evans L. Markowitz L. Williams C. Fredua B. McNamara L. A. Stokley S. Singleton J. A. Singleton J. A. (2021). National regional state and selected local area vaccination coverage among adolescents aged 13-17 years\u2014United States 2020. Morbidity and Mortality Weekly Report 75 1183-1190. https:\/\/doi.org\/10.15585\/mmwr.mm7035a1","DOI":"10.15585\/mmwr.mm7035a1"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Rane M. S. Page L. C. McVeigh E. Miller K. Baure D. Elizabeth Halloran M. Duchin J. S. (2021). Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns. Vaccine 39(12) 1765-1772. https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.006","DOI":"10.1016\/j.vaccine.2021.02.006"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Satterwhite C. L. Torrone E. E. Meites E. F. Dunne E. F. Mahajan R. Ocfemia M. C. B. Su J. Xu F. Weinstock H. (2013). Sexually transmitted infections among US women and men: Prevalence and incidence estimates 2008. Sexually Transmitted Diseases 40(3) 187-193. https:\/\/doi.org\/10.1097\/OLQ.0b013e318286bb53","DOI":"10.1097\/OLQ.0b013e318286bb53"},{"key":"e_1_3_3_39_1","doi-asserted-by":"crossref","unstructured":"Senkomago V. Henley S. J. Thomas C. C. Mix J. M. Markowitz L. E. Saraiya M. (2019). Human papillomavirus-attributable cancers\u2014United States 2012-2016. Morbidity and Mortality Weekly Report 68(33) 724-728. https:\/\/doi.org\/10.15585\/mmwr.mm6833a3","DOI":"10.15585\/mmwr.mm6833a3"},{"key":"e_1_3_3_40_1","doi-asserted-by":"crossref","unstructured":"Shimabukuro T. T. Su J. R. Marquez P. L. Mba-Jonas A. Arana J. E. Cano M. V. (2019). Safety of the 9-valent human papillomavirus vaccine. Pediatrics 144(6) Article e20191791. https:\/\/doi.org\/10.1542\/peds.2019-1791","DOI":"10.1542\/peds.2019-1791"},{"key":"e_1_3_3_41_1","doi-asserted-by":"crossref","unstructured":"Sonawane K. Suk R. Chiao E. Y. Chhatwal J. Qiu P. Wilkin T. Nyitray A. G. Sikora A. G. Deshmukh A. A. (2017). Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection NHANES 2011 to 2014. Annals of Internal Medicine 167(10) 714-724. https:\/\/doi.org\/10.7326\/M17-1363","DOI":"10.7326\/M17-1363"},{"key":"e_1_3_3_42_1","unstructured":"U.S. Department of Health and Human Services. (2020). Guide to community preventive services. About the Community Preventive Services Task Force. https:\/\/www.thecommunityguide.org\/task-force\/about-community-preventive-services-task-force"},{"key":"e_1_3_3_43_1","doi-asserted-by":"crossref","unstructured":"Vanderpool R. C. Breheny P. J. Tiller P. A. Huckelby C. A. Edwards A. D. Upchurch K. D. Phillips C. A. Weyman C. F. (2015). Implementation and evaluation of a school-based human papillomavirus vaccination program in Rural Kentucky. American Journal of Preventive Medicine 49(2) 317-323. https:\/\/doi.org\/10.1016\/j.amepre.2015.05.001","DOI":"10.1016\/j.amepre.2015.05.001"},{"key":"e_1_3_3_44_1","doi-asserted-by":"crossref","unstructured":"Walling E. B. Benzoni N. Dornfeld J. Bhandari R. Sisk B. A. Garbutt J. Colditz G. (2016). Interventions to improve HPV vaccine uptake: A systematic review. Pediatrics 138(1) Article e20153863. https:\/\/doi.org\/10.1542\/peds.2015-3863","DOI":"10.1542\/peds.2015-3863"},{"key":"e_1_3_3_45_1","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski K. A.","year":"2015","unstructured":"Workowski K. A., Bolan G. A. (2015). Sexually transmitted diseases treatment guidelines, 2015 [Recommendations and reports]. Morbidity and Mortality Weekly Report, 64, 1-137.","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"6","key":"e_1_3_3_46_1","first-page":"25","article-title":"Genital warts: A comprehensive review","volume":"5","author":"Yanofsky V.","year":"2012","unstructured":"Yanofsky V., Patel R., Goldenberg G. (2012). Genital warts: A comprehensive review. Journal of Clinical and Aesthetic Dermatology, 5(6), 25-36.","journal-title":"Journal of Clinical and Aesthetic Dermatology"}],"container-title":["NASN School Nurse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1942602X221151134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1942602X221151134","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1942602X221151134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:09:49Z","timestamp":1777590589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1942602X221151134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1177\/1942602X221151134"],"URL":"https:\/\/doi.org\/10.1177\/1942602x221151134","relation":{},"ISSN":["1942-602X","1942-6038"],"issn-type":[{"value":"1942-602X","type":"print"},{"value":"1942-6038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]}}}